Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.60 |
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19995523 | 0.85 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2GAAMAPT | |
| SCHEMBL19995974 | 0.85 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2GAAMAPT | |
| SCHEMBL20005706 | 0.83 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2GAAMAPT | |
| SCHEMBL23220399 | 0.81 | RAB9A (0.61) | RAB9ANPC1SMN1; SMN2GAAMAPT | |
| SCHEMBL20005708 | 0.81 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2GAAMAPT | |
| SCHEMBL20005704 | 0.79 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2GAAMAPT | |
| SCHEMBL23220400 | 0.79 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2GAAMAPT | |
| SCHEMBL20005707 | 0.78 | NPC1 (0.62) | RAB9ANPC1SMN1; SMN2GAAMAPT | |
| SCHEMBL23951675 | 0.77 | KMT2A (0.67) | RAB9ANPC1SMN1; SMN2GAAMAPT | |
| SCHEMBL23220397 | 0.77 | NPC1 (0.57) | RAB9ANPC1SMN1; SMN2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | RAB9A 967/4885NPC1 271/4885SMN1; SMN2 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.